10-K · April 29, 2026
Myomo reported a revenue of $11.35 million for Q4 2025, exceeding estimates by 10.21%. However, it recorded a GAAP EPS loss of $(0.09), consistent with consensus expectations. Notably, its gross margin improved to…
Earnings analysis · 10-Q
MYO earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Myomo reported Q1 2026 revenue of $10.1 million, a 3% increase year-over-year, surpassing estimates by 9.3%. EPS came in at $(0.07), beating the estimate of $(0.12) and reflecting reduced net losses compared to the…
Read full summary
Myomo reported Q1 2026 revenue of $10.1 million, a 3% increase year-over-year, surpassing estimates by 9.3%. EPS came in at $(0.07), beating the estimate of $(0.12) and reflecting reduced net losses compared to the previous period. Management anticipates revenue growth in Q2, backed by increased patient referrals and productivity in the O&P channel.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.07
- Gross margin
- 68.2%
What stood out
-
Revenue Beats Estimates
Actual revenue of $10.1 million exceeded estimates by 9.3% ($925,184).
-
Improved EPS Performance
EPS of $(0.07) surpassed the estimate of $(0.12), showing a positive surprise of 41.67%.
-
Gross Margin Growth
Gross margin increased to 68.2%, up from 67.2% YoY due to lower material costs.
-
Segment Growth in International Sales
International revenue grew to $2.0 million, a rise from $1.3 million in Q1 2025.
-
Reduced Operating Cash Flow Loss
Net cash used in operating activities improved to $(2.2) million from $(2.7) million YoY.
-
Continued Debt Management
A term loan of $17.5 million was secured, with the first tranche of $12.5 million utilized to repay previous debts.
What to watch
-
Ongoing Dependence on Medicare
The business relies heavily on Medicare reimbursement, which poses risks if policies change.
-
Increased Competition in O&P Channel
Growing competitors in the orthopedic and prosthetics market could pressure market share.
-
Potential Import Tariffs Impact
Tariffs on imports are estimated to impact gross margin by less than 1%, posing a risk as tariffs could escalate.
Management's outlook
Management expects Q2 2026 revenue between $10.3 million and $10.8 million.
Earlier filings 4
10-K · March 9, 2026
Myomo positions itself as the market leader in myoelectric limb orthotics with a clear product roadmap (MyoPro2x released April 2025; MyoPro3 and pediatric MyoPal planned). Q4 2025 revenue beat at $11,353,000 with a…
10-Q · May 7, 2025
Myomo reported Q1 product revenue of $9,831,814 (vs $3,754,389 in Q1 2024) and GAAP net loss of $3,465,058, or $(0.08) per share. Gross margin improved to 67.2% while operating margin remained negative at -35.8%;…
10-K · March 10, 2025
Myomo’s 10-K emphasizes a focused strategy to be the market leader in myoelectric limb orthotics (the MyoPro line) with a product roadmap that includes MyoPro3 and a pediatric MyoPal. The filing highlights durable…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.